Abstract
Progyny will release its fourth-quarter fiscal 2025 results on February 26, 2026 Post Market; this preview summarizes consensus projections for revenue, margins, and EPS, along with segment trends and prevailing analyst sentiment.
Market Forecast
The market currently expects Progyny’s fourth-quarter revenue of $307.45 million, year-over-year growth of 11.12%, with estimated EBIT of $40.04 million and adjusted EPS of $0.15, implying a projected year-over-year EPS increase of 41.74%. Consensus points to stable gross profit efficiency and an improving net earnings trajectory; revenue growth is forecast to be supported by core client utilization and benefit-plan expansion. The main fertility benefits business is expected to remain the primary contributor with continued growth, while pharmacy benefits services are anticipated to be the most promising segment by share gain and utilization uplift, given its rising attachment rate and broader medication coverage.
Last Quarter Review
Progyny’s prior quarter delivered revenue of $313.35 million, a gross profit margin of 23.24%, GAAP net profit attributable to the parent company of $13.86 million, a net profit margin of 4.42%, and adjusted EPS of $0.15, with revenue rising 9.32% year-over-year and adjusted EPS increasing 36.36% year-over-year. One notable highlight was revenue outperformance versus internal estimates, reflecting strong benefit-plan adoption among enterprise customers and consistent member engagement. In the main business, fertility benefits services generated $201.95 million, while pharmacy benefits services contributed $111.40 million; together they underscore robust client demand across services, with ongoing momentum in treatment cycles and medication usage.
Current Quarter Outlook
Main Fertility Benefits Business
Progyny’s fertility benefits business remains central to quarterly performance, anchoring revenue scale and margin profile. The segment’s prior-quarter revenue base of $201.95 million provides an operational platform for continued growth from contracted employer additions and member utilization, which are typically seasonally resilient into year-end and early-year benefits cycles. With benefit plan renewals and expansions, per-employer covered lives are likely to expand, supporting consistent cycle starts and average revenue per case. Pricing discipline and program design—such as integrated nurse support and outcomes-based care—help stabilize gross margin even as utilization fluctuates. This quarter, management guidance and market models imply utilization-tailored growth without material discounting, suggesting gross margin continuity around the recent 23.24% level, while net margin improvement is tied to scale benefits and controlled operating expenses.
Pharmacy Benefits Services
Pharmacy benefits services stand out as the most promising growth lever on an attachment-rate and utilization basis. The segment’s last-quarter revenue of $111.40 million reflects broad medication coverage alongside the fertility benefits offering, which has been increasingly adopted by employers to reduce member complexity and improve outcomes. As more clients integrate pharmacy with core benefits, prescription adherence and cycle completion support revenue mix upgrade. The forecasted company-wide revenue growth of 11.12% year-over-year implies pharmacy’s contribution rising proportionally, with potential incremental margin accretion through improved procurement terms and distribution efficiency. Operationally, pharmacy often exhibits lower seasonality relative to procedure timing, helping smooth quarter-to-quarter volatility and reinforcing earnings visibility when combined with disciplined cost controls. Any expansion in medication formularies or contracted rebates could modestly lift EBIT beyond the current $40.04 million estimate.
Key Stock Price Drivers This Quarter
The most impactful near-term drivers include revenue trajectory versus the $307.45 million estimate, operating leverage translating into EPS at or above $0.15, and management commentary on 2026 client additions and attachment rates. A beat on revenue combined with EBIT tracking to the $40.04 million estimate would signal durable demand and margin resilience despite macro uncertainties around employer hiring and benefits budgets. Conversely, any miss due to slower utilization or delayed cycle starts would weigh on sentiment, particularly if gross margin deviates from the recent 23.24% profile or if net margin fails to expand from 4.42%. Guidance color on pharmacy penetration, outcomes metrics, and renewal season wins will likely shape expectations for full-year growth, while clarity on cost cadence—technology spend, partner fees, and care management—will frame EPS durability.
Analyst Opinions
Analyst and institutional commentary over the last six months has skewed bullish, with a majority highlighting consistent client demand and expanding integrated-pharmacy adoption as key supports for revenue growth and margin progression. Several well-followed firms point to Progyny’s visibility from contracted employers and stable utilization as underpinning the double-digit revenue forecast near $307.45 million, while also noting the positive trajectory for adjusted EPS to approximately $0.15. The bullish cohort expects EBIT around $40.04 million to reflect improved scale dynamics and disciplined expense management, with some upside if pharmacy rebates and operational efficiencies come through more quickly. These views emphasize the strategic value of integrated benefits in reducing member friction and improving outcomes, which sustains client retention and expansions. In contrast, bearish commentary is less prevalent and tends to center on potential normalization of cycle utilization and employer budget scrutiny; however, such caution has not dominated recent previews. Overall, the prevailing stance anticipates steady revenue expansion and healthy margin trends into the quarter, with attention on guidance signals for attachment-rate growth and employer pipeline quality through the first half of 2026.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments